Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed adenocarcinoma of the breast.
Metastatic disease must be measurable or evaluable
Relapsed or progressed during prior treatment with single-agent NSAI, meeting either of the following criteria:
NSAI given as adjuvant therapy that lasted ≥ 12 months OR
Achieved an objective CR, PR, or SD that that lasted ≥ 6 months after prior 1st-line
Female postmenopausal patients
You may not be if
Hormone receptor status1. ER -ve and PgR NK2. ER-ve and PgR -ve3. ER NK
Prescribed Tamoxifen for metastatic disease
Rapidly progressive visceral disease
Patients with malignancies within the last 5 years.
Clareo Health | Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
